Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma

Wednesday, April 5, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 5, 2017 /PRNewswire/ --

On Tuesday, benchmark US indices were in bullish colors as the NASDAQ Composite

closed the trading session up 0.07%; the Dow Jones Industrial Average edged 0.19% higher; and the S&P 500 was up 0.06%. US markets saw a mixed session as 3 sectors closed in green, 3 sectors finished in red, and 3 sectors ended flat for the day.
Pre-market today, reviews these four Biotechnology stocks: Puma Biotechnology Inc. (NASDAQ: PBYI), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Calithera Biosciences Inc. (NASDAQ: CALA), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Learn more about these stocks by accessing their free research reports at:

Puma Biotechnology  

On Tuesday, shares in Los Angeles, California headquartered Puma Biotechnology Inc. ended the session 1.66% lower at $35.50 with a total volume of 864,385 shares traded. Puma Biotechnology's shares have advanced 5.50% in the last one month and 12.70% in the previous three months. Furthermore, the stock has gained 22.08% in the past one year. The stock is trading 4.19% below its 50-day moving average and 17.11% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of products to improve cancer care, have a Relative Strength Index (RSI) of 41.42. Free research report on PBYI is available at:

Regeneron Pharma  

On Tuesday, shares in Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 681,157 shares. The stock ended the day 0.07% lower at $382.92. Shares of the Company are trading at a PE ratio of 49.67. Regeneron Pharma's stock has advanced 0.26% in the last one month and 0.85% in the previous three months. The Company's shares are trading above its 50-day and 200-day moving averages by 3.02% and 0.16%, respectively. Furthermore, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 52.77.

On March 29th, 2017, research firm UBS reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $435 a share to $446 a share. The complimentary research report on REGN can be downloaded at:


South San Francisco, California headquartered Calithera Biosciences Inc.'s stock finished Tuesday's session 1.35% lower at $11.00 with a total volume of 465,209 shares traded. Over the last three months and the previous one year, Calithera Biosciences' shares have rallied 205.56% and 94.35%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 12.18% and 122.23%, respectively. Shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 48.11.

On April 03rd, 2017, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock. Visit us today and access our complete research report on CALA at:

Lexicon Pharma  

The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s stock edged 0.49% higher, to close the day at $14.26. The stock recorded a trading volume of 679,688 shares. Lexicon Pharma's shares have advanced 0.42% in the previous three months and 11.76% in the past one year. The Company's shares are trading 4.53% and 8.33% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the company, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 43.57. Get free access to your research report on LXRX at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store